These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33253391)

  • 21. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial).
    Mathiasen AB; Jørgensen E; Qayyum AA; Haack-Sørensen M; Ekblond A; Kastrup J
    Am Heart J; 2012 Sep; 164(3):285-91. PubMed ID: 22980293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis.
    Riordan NH; Morales I; Fernández G; Allen N; Fearnot NE; Leckrone ME; Markovich DJ; Mansfield D; Avila D; Patel AN; Kesari S; Paz Rodriguez J
    J Transl Med; 2018 Mar; 16(1):57. PubMed ID: 29523171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).
    Mathiasen AB; Qayyum AA; Jørgensen E; Helqvist S; Fischer-Nielsen A; Kofoed KF; Haack-Sørensen M; Ekblond A; Kastrup J
    Eur Heart J; 2015 Jul; 36(27):1744-53. PubMed ID: 25926562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
    Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
    Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II).
    Lamo-Espinosa JM; Mora G; Blanco JF; Granero-Moltó F; Nuñez-Córdoba JM; Sánchez-Echenique C; Bondía JM; Aquerreta JD; Andreu EJ; Ornilla E; Villarón EM; Valentí-Azcárate A; Sánchez-Guijo F; Del Cañizo MC; Valentí-Nin JR; Prósper F
    J Transl Med; 2016 Aug; 14(1):246. PubMed ID: 27565858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS.
    Staff NP; Madigan NN; Morris J; Jentoft M; Sorenson EJ; Butler G; Gastineau D; Dietz A; Windebank AJ
    Neurology; 2016 Nov; 87(21):2230-2234. PubMed ID: 27784774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis.
    Oh KW; Noh MY; Kwon MS; Kim HY; Oh SI; Park J; Kim HJ; Ki CS; Kim SH
    Ann Neurol; 2018 Sep; 84(3):361-373. PubMed ID: 30048006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Use of Intrathecal Mesenchymal Stem Cells in patients with Multiple Sclerosis: A Pilot Study with Booster Injection.
    Sahraian MA; Mohyeddin Bonab M; Baghbanian SM; Owji M; Naser Moghadasi A
    Immunol Invest; 2019 Feb; 48(2):160-168. PubMed ID: 30156938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.
    Yamout B; Hourani R; Salti H; Barada W; El-Hajj T; Al-Kutoubi A; Herlopian A; Baz EK; Mahfouz R; Khalil-Hamdan R; Kreidieh NM; El-Sabban M; Bazarbachi A
    J Neuroimmunol; 2010 Oct; 227(1-2):185-9. PubMed ID: 20728948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple transplantation of mesenchymal stem cells in a patient with active progressive multiple sclerosis: Long term therapeutic outcomes.
    Liu S; Mao X; Hou Z; Wei H; Gao H; Liu Y; Xie Y; Tang W; He S; Zhao Y; Wang W; Li L; Wang X; Meng M
    Clin Neurol Neurosurg; 2022 Dec; 223():107475. PubMed ID: 36274549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.
    Harris VK; Yan QJ; Vyshkina T; Sahabi S; Liu X; Sadiq SA
    J Neurol Sci; 2012 Feb; 313(1-2):167-77. PubMed ID: 21962795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial.
    Matas J; Orrego M; Amenabar D; Infante C; Tapia-Limonchi R; Cadiz MI; Alcayaga-Miranda F; González PL; Muse E; Khoury M; Figueroa FE; Espinoza F
    Stem Cells Transl Med; 2019 Mar; 8(3):215-224. PubMed ID: 30592390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy.
    Singer W; Dietz AB; Zeller AD; Gehrking TL; Schmelzer JD; Schmeichel AM; Gehrking JA; Suarez MD; Sletten DM; Minota Pacheco KV; Coon EA; Sandroni P; Benarroch EE; Fealey RD; Matsumoto JY; Bower JH; Hassan A; McKeon A; Windebank AJ; Mandrekar JN; Low PA
    Neurology; 2019 Jul; 93(1):e77-e87. PubMed ID: 31152011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study.
    Mohyeddin Bonab M; Yazdanbakhsh S; Lotfi J; Alimoghaddom K; Talebian F; Hooshmand F; Ghavamzadeh A; Nikbin B
    Iran J Immunol; 2007 Mar; 4(1):50-7. PubMed ID: 17652844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.
    De Keersmaecker AV; Van Doninck E; Popescu V; Willem L; Cambron M; Laureys G; D' Haeseleer M; Bjerke M; Roelant E; Lemmerling M; D'hooghe MB; Derdelinckx J; Reynders T; Willekens B
    Front Immunol; 2024; 15():1362629. PubMed ID: 38680485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.